{"id":"akynzeo-solution","safety":{"commonSideEffects":[{"rate":"8-12%","effect":"Headache"},{"rate":"5-8%","effect":"Constipation"},{"rate":"3-5%","effect":"Fatigue"},{"rate":"2-4%","effect":"Diarrhea"},{"rate":"2-3%","effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Netupitant blocks neurokinin-1 (NK1) receptors, which are involved in the central processing of emetic signals, particularly for delayed nausea and vomiting. Palonosetron blocks serotonin 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone, addressing acute nausea and vomiting. The dual mechanism provides comprehensive coverage across both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).","oneSentence":"Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:56.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy"},{"name":"Prevention of CINV in patients receiving moderately emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT06840769","phase":"PHASE1","title":"A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers","status":"TERMINATED","sponsor":"Helsinn Healthcare SA","startDate":"2023-06-17","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT03204279","phase":"PHASE2","title":"PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2017-08-31","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":67},{"nctId":"NCT03403712","phase":"PHASE3","title":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2018-03-16","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":404},{"nctId":"NCT02517021","phase":"PHASE3","title":"A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-11","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":405}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IV Akynzeo®","Olanzapine"],"phase":"marketed","status":"active","brandName":"Akynzeo solution","genericName":"Akynzeo solution","companyName":"Helsinn Healthcare SA","companyId":"helsinn-healthcare-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, Prevention of CINV in patients receiving moderately emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}